Tiragolumab

• Roche will acquire Poseida Therapeutics for $1.0 billion, expanding its CAR-T therapy portfolio, targeting hematological malignancies, solid tumors, and autoimmune diseases. • Merck's Winrevair phase III study met its primary endpoint, showing a statistically significant reduction in morbidity or mortality events in advanced pulmonary arterial hypertension. • AstraZeneca's Truqap, combined with Zytiga and ADT, significantly improved radiographic progression-free survival in PTEN-deficient metastatic hormone-sensitive prostate cancer. • Novartis received European Commission approval for Kisqali to treat HR+/HER2- early breast cancer patients at high risk of disease recurrence, based on the NATALEE phase III trial.

• Belrestotug, an anti-TIGIT antibody from GSK and iTeos, demonstrated a higher objective response rate (ORR) when combined with GSK's Jemperli (dostarlimab) in PD-L1-positive NSCLC patients. • The GALAXIES Lung-02 phase 2 trial showed a dose-response relationship with belrestotug, with the highest dose achieving a 76.7% ORR compared to 28.1% for Jemperli alone. • While side effects were generally manageable, the combination therapy had higher treatment discontinuation rates and some treatment-related deaths, warranting careful safety monitoring. • A phase 3 trial, GALAXIES-Lung-301, is planned using the 400mg dose of belrestotug in combination with Jemperli, comparing it to Keytruda plus placebo in first-line NSCLC patients.